Latest news and press releases about Equillium, Inc. (EQ): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
Price
| Price | $1.89 |
| Market Cap | $119M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.77 |
| EV / EBITDA | -5.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -41.15% |
| Return on Invested Capital | -34.10% |
| Return on Assets | -30.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: COEP · CUE · FBIO · IPSC · MDCX · NRXP · OSTX
Explore sector: Healthcare · Biotechnology
More sections of EQ: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks